JP6219588B2 - Blood oxygen carrying capacity improver - Google Patents

Description

  The present invention relates to a blood oxygen carrying capacity improver.

  In sports competitions, oxygen carrying capacity is an important factor that leads to improved performance. Athletes may perform high altitude training, for example, in order to improve oxygen carrying capacity. However, high altitude training has the inconvenience of having to stay in high altitudes for a long time, and it also costs expenses such as stay costs. Furthermore, there are various problems such as the possibility of causing symptoms of altitude sickness (for example, fatigue, decreased appetite, digestive absorption disorder, etc.).

  In addition, a method for improving oxygen carrying capacity by hormone administration or the like is known. However, this method is regarded as a so-called doping violation. For this reason, there is a need for an economical and safe method that is different from conventional methods that athletes can use to improve oxygen carrying capacity.

  Patent Document 1 discloses an oxygen transport ability improving agent using a compound that reduces the oxygen affinity of hemoglobin in erythrocytes. However, this drug temporarily promotes the dissociation of oxygen from hemoglobin and increases the oxygen supply to the tissue. By increasing the number of red blood cells and the amount of iron stored in the body, It does not increase the holding amount.

  Patent Document 2 discloses an iron absorption promoting composition for improving anemia containing nicotianamine as an active ingredient. However, since the anemia improvement effect by this composition is based on the iron absorption promoting action, an anemia improvement effect can be expected only for iron deficiency anemia.

  Patent Document 3 discloses a composition having a hematopoietic stimulating action characterized by containing a fruit body and / or mycelium of Hanabiratake as an active ingredient. However, since natural products are used as active ingredients, the cost increases.

  Patent Document 4 discloses a composition that suppresses a decrease in erythropoietic function including amino acids including methionine. However, it is difficult to increase the amount of hemoglobin even if it can prevent the decrease in the amount of hemoglobin only by administering amino acid. Furthermore, amino acids are not suitable for oral intake because they do not taste good. In addition, the cost increases.

  Patent Document 5 discloses a composition having an ability to remove at-risk risk factors containing an n-3 polyunsaturated fatty acid as an active ingredient, and shows that an erythrocyte membrane strengthening effect can be obtained. However, n-3 polyunsaturated fatty acids have no effect of increasing red blood cells or hemoglobin.

JP 07-145049 A JP 2007-153807 A JP 2008-069080 A International Publication No. 2009/066562 JP-A-11-239464

  An object of the present invention is to provide a blood oxygen carrying capacity improver.

  As a result of intensive studies to solve the above-mentioned problems, the present inventors have found that a combination of a predetermined mineral and a vitamin component can improve blood oxygen carrying capacity, and have completed the present invention. .

That is, the present invention includes the following.
[1] A blood oxygen carrying capacity improver comprising vitamin B6, vitamin B12, vitamin C, folic acid, iron, zinc, and copper.
[2] Vitamin B6, Vitamin B12, Vitamin C, Folic acid, Iron, Zinc, and Copper are 0.5-100 mg, 0.6-3000 μg, 50-2000 mg, 60-1000 μg, 2.25 per daily dose, respectively. The blood oxygen carrying ability improver of the above-mentioned [1], comprising 45 mg, 2.1-30 mg, and 0.18-9 mg.
[3] The blood oxygen transport capacity improver according to [1] or [2] above, wherein the improvement of blood oxygen transport capacity is accompanied by an increase in the amount of iron stored in the body.
[4] Any of the above-mentioned [1] to [3], further comprising at least one selected from the group consisting of vitamin A, vitamin D, vitamin E, vitamin B1, vitamin B2, pantothenic acid, niacin and selenium Blood oxygen carrying capacity improver.
[5] The blood oxygen carrying capacity improver according to the above [1] to [4], comprising protein, carbohydrate, and ash.
[6] The blood oxygen transport capacity improver according to the above [1] to [5], comprising a unit package form per serving.
[7] The blood oxygen carrying capacity improver according to the above [1] to [6] for athletes.
[8] The blood oxygen transport capacity improver according to the above [1] to [7], which is for oral use.

  According to the present invention, blood oxygen carrying capacity can be improved in, for example, athletes.

Hereinafter, the present invention will be described in detail.
The present invention relates to a blood oxygen carrying capacity improver containing vitamins and minerals. The blood oxygen carrying capacity improver according to the present invention typically comprises a composition that improves blood oxygen carrying capacity. Specifically, the blood oxygen carrying capacity improver according to the present invention contains vitamin B6, vitamin B12, vitamin C, folic acid, iron, zinc, and copper. The blood oxygen transport capacity improver according to the present invention is 0.5-100 mg vitamin B6, 0.6-3000 μg vitamin B12, 50-2000 mg vitamin C, 60-1000 μg folic acid, and 2 iron per daily dose. .25-45 mg, 2.1-30 mg zinc, and 0.18-9 mg copper. The blood oxygen carrying capacity improver according to the present invention may contain 1 to 50 mg, more preferably 2 to 30 mg, and further preferably 3 to 12 mg of vitamin B6 per daily dose. The blood oxygen carrying capacity improver according to the present invention may preferably contain 1-1000 μg, more preferably 5-100 μg, and even more preferably 5-30 μg of vitamin B12 per daily dose. The blood oxygen carrying capacity improver according to the present invention may contain vitamin C, preferably 75 to 1000 mg, more preferably 100 to 800 mg, and still more preferably 200 to 500 mg per daily dose. The blood oxygen carrying capacity improver according to the present invention may contain 90 to 800 μg, more preferably 120 to 600 μg, and even more preferably 150 to 400 μg of folic acid per daily dose. The blood oxygen carrying capacity improver according to the present invention may contain iron in an amount of preferably 3 to 35 mg, more preferably 4.5 to 25 mg, and still more preferably 5 to 20 mg per daily dose. The blood oxygen carrying capacity improver according to the present invention may contain 3 to 25 mg, more preferably 4 to 20 mg, and further preferably 5 to 15 mg of zinc per daily dose. The blood oxygen carrying capacity improver according to the present invention may contain 0.2 to 5 mg, more preferably 0.3 to 3 mg, and still more preferably 0.3 to 1 mg of copper per daily dose. For example, the blood oxygen carrying capacity improver according to the present invention is 4-8 mg vitamin B6, 10-20 μg vitamin B12, 300-350 mg vitamin C, 180-300 μg folic acid, 6-10 mg iron per daily dose. 7-10 mg of zinc and 0.3-0.6 mg of copper may be included.

  With regard to the blood oxygen carrying capacity improver according to the present invention, “containing vitamin B6 per day dose of Xg” means that the amount of vitamin B6 contained in the blood oxygen carrying capacity improver according to the present invention is the blood oxygen carrying capacity according to the present invention. It means that the amount is Xg when converted into daily administration or intake (daily dose) of the performance enhancer. Specifically, for example, in the case of the specific blood oxygen carrying capacity improver according to the present invention having a daily dose of 200 g, Xg vitamin B6 is contained in 200 g of the blood oxygen carrying capacity improver, and 100 g Contains one half of Xg of vitamin B6. In the present invention, the “daily dose” of the individual blood oxygen carrying capacity improver can be appropriately determined by those skilled in the art within a range that does not cause adverse health effects. The description regarding the content of vitamin B12, vitamin C, folic acid, iron, zinc, copper and other components of the blood oxygen transport capacity improver according to the present invention is also understood in the same manner as described above.

  The blood oxygen carrying capacity improver according to the present invention is other vitamins such as vitamin A, vitamin D, vitamin E, vitamin K, vitamin B1, vitamin B2, pantothenic acid, niacin, biotin, and / or other minerals. For example, calcium, phosphorus, magnesium, potassium, iodine, manganese, selenium, chromium, molybdenum and the like may be further included. For example, the blood oxygen transport capacity improving agent according to the present invention is at least one selected from the group consisting of vitamin A, vitamin D, vitamin E, vitamin B1, vitamin B2, pantothenic acid, niacin, sodium and selenium, for example, All may be further included. For example, the blood oxygen carrying capacity improver according to the present invention may contain 150 to 1800 μg RE, preferably 300 to 900 μg RE of vitamin A, and 1.3 to 15 μg, preferably 2.5 to 7 vitamin D per daily dose. Vitamin E 7.5-90 mg, preferably 15-45 mg, vitamin K 0.5-6.0 μg, preferably 1.0-3.0 μg, vitamin B1 0.8-9.0 mg, preferably 1.5-4.5 mg, vitamin B2 1.0-12.0 mg, preferably 2.0-6.0 mg, 3 pantothenic acid -36 mg, preferably 6-18 mg, niacin 8-96 mg NE, preferably 16-48 mg NE, biotin 0.5-6.8 g, preferably may comprise 0.9～3.4Myug. The blood oxygen carrying capacity improver according to the present invention may also contain, for example, 5 to 50 mg, preferably 9 to 27 mg of calcium, 15 to 150 mg, preferably 30 to 90 mg of phosphorus per daily dose. 2.4 to 25 mg, preferably 4.2 to 12.6 mg, potassium 45 to 500 mg, preferably 90 to 270 mg, and iodine 0.2 to 4 μg, preferably 0.5 to 2 μg. May contain 0.01 to 0.20 mg of manganese, preferably 0.03 to 0.10 mg, 6 to 72 μg of selenium, preferably 12 to 36 μg, and 5 to 50 μg of chromium, preferably It may contain 9 to 27 μg, and may contain 0.2 to 4.0 μg of molybdenum, preferably 0.5 to 2.0 μg.

  The blood oxygen carrying capacity improver according to the present invention contains other biological substances such as vegetable juice, fruit juice, peptide, plant extract, animal extract, edible yeast, dietary fiber, lipid, protein, carbohydrate (carbohydrate) and the like. Further, it may be included. The blood oxygen carrying ability improving agent according to the present invention may further contain other components having an effect of improving blood oxygen carrying ability.

  In a preferred embodiment, the blood oxygen transport capacity improver according to the present invention may contain 0.18 to 10.0 g, preferably 0.35 to 5.0 g of protein per daily dose as a general composition. Sugar) may be included in an amount of 2.5 to 30 g, preferably 5 to 15 g, and ash may be included in an amount of 0.15 to 1.8 g, preferably 0.3 to 0.9 g. In a preferred embodiment, the blood oxygen carrying capacity improver according to the present invention may contain 30 to 400 g, preferably 60 to 180 g of water per daily dose as a general composition. Proteins and carbohydrates may be derived from animals, plants, or microorganisms.

  The blood oxygen carrying capacity improver according to the present invention is also a pharmaceutical or food additive, for example, a stabilizer, a buffer, a surfactant, a pH adjuster, a sweetener, a fragrance, a preservative, a colorant, and an excipient. An agent, a carrier, a solvent, a coating agent and the like may be further included.

  The blood oxygen carrying ability improver according to the present invention may be solid, gel, or liquid, and more preferably liquid. The blood oxygen carrying ability improver according to the present invention may be in any form such as tablet, granule, powder, capsule, aqueous solution, suspension, emulsion, syrup, jelly, gel and the like. The agent for improving blood oxygen carrying ability according to the present invention may be in the form of a dried product intended to be dissolved in a liquid solvent before use. The blood oxygen carrying capacity improver according to the present invention is a food (preferably a functional food such as a supplement or a food for specified health use) as long as it is intended to improve the blood oxygen carrying capacity. ) May be manufactured.

  In addition, the blood oxygen carrying capacity improver according to the present invention is preferably packaged in a unit amount per serving from the viewpoint of hygiene during intake and ease of handling during transportation and storage. Therefore, this invention also provides the blood oxygen carrying capacity improvement agent which consists of a unit package form per meal. “Blood oxygen transportability improver consisting of a unit package per meal” means a blood oxygen transportability improver packaged in a unit amount per serving. Specific examples thereof include, but are not limited to, liquid agents and jelly agents filled in containers such as packs, cups, and bottles. The unit amount per serving can be, for example, 50 g to 500 g (or 50 mL to 500 mL), preferably 75 g to 300 g (or 75 mL to 300 mL), and more preferably 100 g to 200 g (or 100 mL to 200 mL). Here, “unit amount per meal” means a predetermined amount (a single intake) that is assumed to be taken at one time. The “predetermined amount that is supposed to be ingested at one time” may be an amount that is expected to complete the intake of the entire amount within a relatively short time. It is not limited to the amount etc. which can be ingested continuously or continuously. The “unit amount per meal” may be, for example, a daily dose of the blood oxygen transport capacity improving agent according to the present invention, or an amount obtained by dividing the daily dose (for example, 1/2 to 1/10 of the daily dose). ).

  The blood oxygen carrying ability improver according to the present invention may have an osmotic pressure of 50 to 800 mOsm / L in the liquid state.

  As long as the blood oxygen transport capacity improving agent according to the present invention is taken into the body via the gastrointestinal tract, even if it is for oral use, it can be administered parenterally (for example, administration via the gastrointestinal tract such as intragastric and enteral administration). In particular, those prepared for oral use are preferred. In the present invention, regardless of whether it is oral or parenteral, it is also referred to as “ingestion” to mean that it is taken into the body via the digestive tract (stomach or intestine). In the present specification, “intake” and “administration” may be used interchangeably.

  The blood oxygen carrying capacity improver according to the present invention may be prepared by mixing each component into one, or prepared using various other formulation techniques and food processing techniques well known to those skilled in the art. Also good. In the preparation of the blood oxygen carrying capacity improver according to the present invention, the above-described components, or salts thereof that are acceptable as pharmaceutical additives or food additives may be used as raw materials.

  The blood oxygen carrying ability improving agent according to the present invention as described above brings about an improvement in blood oxygen carrying ability in a subject who has taken it, as compared with before ingestion.

  The blood oxygen carrying ability improving effect of the blood oxygen carrying ability improving agent according to the present invention is ingested with respect to a subject after continuously taking the blood oxygen carrying ability improving agent according to the present invention over a certain period (for example, 2 months). This can be confirmed by an improvement in the blood oxygen carrying capacity index compared to before the period. Examples of the blood oxygen carrying capacity index used here include the number of red blood cells, the amount of hemoglobin (hemoglobin), and MCHC (average red blood cell hemoglobin concentration). MCHC indicates the concentration of hemoglobin contained in one red blood cell, and is calculated as hemoglobin (g / dl) ÷ hematocrit (%) × 100. In the present invention, when the number of red blood cells, the amount of hemoglobin, and MCHC are increased (for example, increased by 3% or more, preferably 5% or more) compared to before the intake period, it is determined that the blood oxygen carrying capacity is improved. be able to. That is, the blood oxygen transport capacity improving agent according to the present invention can increase the number of red blood cells, the amount of hemoglobin, and the MCHC as compared to before the intake period.

  Furthermore, it is preferable that the improvement of the blood oxygen carrying capacity by the blood oxygen carrying capacity improving agent according to the present invention is accompanied by an increase in the amount of iron stored in the body. The increase in the amount of iron stored in the body can be confirmed by an increase in the amount of iron stored in the body, for example, serum ferritin concentration and serum iron concentration. Serum ferritin concentration reflects the amount of stored iron stored in the liver and the like. If both the serum ferritin concentration and the serum iron concentration are increased (for example, an increase of 20% or more, preferably 30% or more) compared to before the intake period, an increase in the amount of iron stored in the body is indicated. Even if the serum iron concentration increases, it can be said that the amount of iron stored in the body has not increased until the serum ferritin concentration increases. Iron is indispensable for the synthesis of hemoglobin that carries blood oxygen carrying capacity, and the iron is replenished from stored iron. Therefore, the increase in the amount of stored iron in the body can bring about a sustained improvement in blood oxygen carrying capacity.

  The blood oxygen carrying capacity index may be measured by a conventional method. For example, the amount of hemoglobin is measured by the SLS-Hb method, the number of red blood cells is measured by the sheath flow electric resistance method, and the hematocrit value for calculating MCHC is measured by The sheath flow electrical resistance method, the measurement of serum ferritin concentration can be performed by enzyme immunoassay, and the measurement of serum iron concentration can be performed by nitroso-PSAP method. These measurements may usually be performed using a commercially available measuring instrument or measuring kit.

  The blood oxygen carrying ability improving agent according to the present invention can be used for improving the blood oxygen carrying ability of an intake (administration) target. Therefore, the blood oxygen carrying capacity improver according to the present invention is also preferably used for subjects for which it is desired to improve blood oxygen carrying capacity. Such subjects are, but not limited to, mammals including humans, domestic animals, pets, experimental (test) animals, etc., with humans being particularly preferred. The administration target may or may not be anemia (for example, a hemoglobin amount of less than 13 g / dL for human men and less than 12 g / dL for human women). When the administration target is anemia, the blood oxygen transport capacity improving agent according to the present invention improves the decreased blood oxygen transport capacity and improves anemia. When the administration subject is not anemia, in addition to preventing anemia, the blood oxygen carrying capacity can be further improved. Furthermore, the blood oxygen transport capacity improver according to the present invention can increase the amount of iron stored in the body in addition to the improvement of blood oxygen transport capacity, and provides a sustained effect of improving blood oxygen transport capacity for the administration subject. Can do. And by administering the blood oxygen carrying ability improving agent according to the present invention, the blood oxygen carrying ability is improved, thereby raising the anaerobic threshold (AT), and as a result, a higher intensity aerobic exercise is performed. It becomes possible and improves endurance. That is, the blood oxygen carrying capacity improver according to the present invention can be effective in improving exercise capacity. Therefore, the subject of the blood oxygen carrying capacity improving agent according to the present invention is particularly preferably a subject who regularly performs exercise or physical labor (especially exercise or labor requiring aerobic exercise or endurance). Specifically, professional and amateur sports athletes, such as athletes, student athletes, sports instructors, physical education teachers, sports enthusiasts, and exercises for health maintenance and dieting such as walking and marathons (especially aerobic) (Exercise), people who are engaged in physical labor, animals engaged in competition and physical labor (racing horses, plowing cattle, hounds, etc.). Among them, an athlete is particularly preferable as an intake subject of the blood oxygen carrying ability improver according to the present invention. In the present invention, an “athlete” is a professional or amateur sports athlete who performs a competition (preferably a competition that requires aerobic exercise or endurance) with the goal of improving his or her performance or athletic ability. Someone who is. By allowing an athlete to take the blood oxygen transport capacity improver according to the present invention, blood oxygen transport capacity can be improved, endurance can be improved, and athlete performance may be improved.

  Accordingly, the present invention provides a blood oxygen carrying capacity improver for subjects intended to improve blood oxygen carrying capacity, particularly a blood oxygen carrying capacity improver for athletes.

  The present invention also provides a method for improving blood oxygen carrying capacity, comprising administering (ingesting) the blood oxygen carrying capacity improving agent according to the present invention to a subject. By administering the blood oxygen carrying ability improving agent according to the present invention, blood oxygen carrying ability can be improved and endurance can be improved. The method of the present invention can also increase the amount of iron stored in the body as well as improve blood oxygen carrying capacity. Therefore, the present invention also provides a method for improving endurance based on the improvement of blood oxygen carrying capacity, which comprises administering (ingesting) the blood oxygen carrying capacity improving agent according to the present invention. In the present invention, the administration subject is the same as described above, and may or may not be anemic. In particular, daily exercise or physical labor (especially exercise or labor requiring aerobic exercise or endurance) A subject who is performing an exercise, and preferably an athlete. Anemia can be improved by administering the blood oxygen carrying ability improving agent according to the present invention to a subject who is anemic. The present invention also provides such an anemia improvement method. On the other hand, by administering the blood oxygen carrying ability improver according to the present invention to a subject who is not anemic, anemia can be prevented and the blood oxygen carrying ability can be further improved. The present invention also provides such an anemia prevention method and a method for improving blood oxygen carrying capacity. In the method according to the present invention, the blood oxygen transport capacity improver according to the present invention is administered to a subject to be administered for a certain period, that is, 3 days or longer, preferably 1 week or longer, more preferably 2 weeks or longer, and further preferably 1 month. For example, it is preferable to administer continuously over 6 months or 1 year. In the method according to the present invention, it is preferable to administer the blood oxygen carrying ability improving agent according to the present invention every day during the administration period, but it may not be administered every day as long as it is continuously administered during the period. The blood oxygen carrying capacity improver according to the present invention may be administered once a day, or may be divided into several times a day.

  Hereinafter, the present invention will be described more specifically with reference to examples. However, the technical scope of the present invention is not limited to these examples.

  About the blood oxygen carrying ability improvement agent which concerns on this invention, the oxygen carrying ability improvement effect and the iron supplement effect were investigated. A liquid test composition containing vitamins and minerals having a composition shown in Table 1 (125 mL / tube) was used as a blood oxygen transport capacity improver according to the present invention.

  The test compositions shown in Table 1 are prepared by dissolving vitamins, sweeteners, fruit juices, and minerals in raw water, mixing well, adjusting the pH by adding a pH adjuster, and then homogenizing using a homogenizer. It was prepared by cooling after sterilization.

  The osmotic pressure of the liquid test composition was 515 mOsm / L, and the viscosity (20 ° C.) was 5 mPa · s.

  For 26 male university athletes (long-distance track athletes) as subjects, the liquid test composition was ingested once a day for 2 months. Blood index measurements were taken before and after the intake period.

  As blood indicators, hemoglobin (hemoglobin) amount, which is an indicator of blood oxygen carrying capacity, red blood cell count, MCHC (mean erythrocyte hemoglobin concentration), serum ferritin concentration, serum iron concentration, which are indicators of body iron storage, were measured. . Hemoglobin is measured by SLS-Hb method, red blood cell count is measured by sheath flow electrical resistance method, hematocrit value for calculating MCHC is measured by sheath flow electrical resistance method, serum ferritin concentration is measured by enzyme immunoassay, serum The iron concentration was measured by the nitroso-PSAP method. Table 2 shows the change in the blood oxygen carrying capacity index before and after the intake period as an average value of 26 subjects.

  Hemoglobin content, red blood cell count, and MCHC all increased after completion of the intake period compared to before the intake period. From this, it was shown that the blood oxygen carrying ability is improved by ingesting the blood oxygen carrying ability improving agent according to the present invention.

  Table 3 shows the change in the body iron storage index before and after the intake period as an average value of 26 subjects.

  Both serum ferritin concentration and serum iron concentration increased after the intake period compared to before the intake period. From this, it was shown that the amount of iron stored in the body is increased by ingestion of the blood oxygen transport capacity improver according to the present invention.

  In addition, Table 4 shows changes in the hemoglobin amount of two subjects who had anemia (hemoglobin amount less than 13 g / dL) before the test beverage ingestion period.

  Both of these two patients showed that the hemoglobin level increased to the normal range after the intake period, and anemia improved. In addition, none of the 26 persons including these 2 persons showed anemia after the intake period.

  The blood oxygen carrying capacity improver according to the present invention can be used to improve blood oxygen carrying capacity. By improving the blood oxygen carrying capacity, the anaerobic threshold (AT) is increased and a higher intensity aerobic exercise is possible. If the blood oxygen carrying ability improving agent according to the present invention is used, an improvement in endurance can be expected by improving the blood oxygen carrying ability. In addition, by applying the blood oxygen carrying capacity improver of the present invention to athletes, blood oxygen carrying capacity is improved, and as a result, economical (use of inexpensive raw materials) and safe (low risk of side effects) of athletes It can be expected to improve the competition results. Furthermore, in addition to improving blood oxygen carrying ability, an effect of preventing and / or improving anemia is also expected.

Claims (8)

In the amount per daily dose, 4~8mg vitamin B6, 10~20μg vitamin B12, 300~350mg vitamin C, folic acid 180~300μg, the iron 6~10mg, zinc 7~10mg, the copper 0. 3 to 0.6 mg, vitamin A 300 to 900 μg RE, vitamin D 2.5 to 7.5 μg, vitamin E 15 to 45 mg, vitamin K 1.0 to 3.0 μg, vitamin B1 1.5 to 4 .5 mg, vitamin B2 2.0-6.0 mg, niacin 16-48 mg NE, biotin 0.9-3.4 μg, pantothenic acid 6-18 mg, potassium 90-270 mg, calcium 9-27 mg, magnesium 4.2-12.6 mg, phosphorus 30-90 mg, manganese 0.03-0.10 mg, chromium 9-27 μg, molybdenum 0 5～2.0Myug, selenium 12～36Myug, including 0.3-0.9 g 0.5～2Myug iodine, protein 0.35～5.0G, carbohydrate 5 to 15 g, the ash content, blood oxygen transport Performance improver. The blood oxygen carrying capacity improver according to claim 1, comprising 60 to 180 g of water per daily dose. The blood oxygen transport capacity improver according to claim 1 or 2, for improving blood oxygen transport capacity, which is indicated by an increase in the number of red blood cells, the amount of hemoglobin, and MCHC (average red blood cell hemoglobin concentration). For blood oxygen carrying capacity improves with increased somatic iron stores, blood oxygen carrying capacity improver according to any one of claims 1-3. The blood oxygen carrying ability improver according to any one of claims 1 to 4 , comprising a unit package form per serving. The blood oxygen carrying capacity improver according to any one of claims 1 to 5 , for athletes. The blood oxygen carrying ability improver according to any one of claims 1 to 6 , which is used for a subject that is not anemia. The blood oxygen carrying ability improver according to any one of claims 1 to 7 , which is for oral use.